Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis

被引:34
|
作者
Barsky, Emily E. [1 ]
Williams, Kathryn A. [2 ]
Priebe, Gregory P. [3 ,4 ]
Sawicki, Gregory S. [1 ]
机构
[1] Boston Childrens Hosp, Div Resp Dis, Dept Med, Boston, MA USA
[2] Boston Childrens Hosp, Clin Res Ctr, Boston, MA USA
[3] Boston Childrens Hosp, Div Crit Care Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA
[4] Boston Childrens Hosp, Div Infect Dis, Dept Med, Boston, MA USA
关键词
cystic fibrosis; pulmonary function tests; respiratory tract infections; Stenotrophomonas maltophilia; PSEUDOMONAS-AERUGINOSA INFECTION; FORCED EXPIRATORY VOLUME; RISK-FACTORS; CHILDREN; ADOLESCENTS; PREDICTORS; MORTALITY; OUTCOMES; FEV1; 2ND;
D O I
10.1002/ppul.23781
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
ObjectivesTo determine whether incident detection of Stenotrophomonas maltophilia (SM) in patients with cystic fibrosis (CF) is associated with accelerated lung function decline and increased hospitalizations and to determine whether this effect is more pronounced in individuals with subsequent chronic infection. MethodsWe performed a longitudinal, retrospective single-center, pre-post study of 88 patients with CF, ages 6-51 years, with first positive respiratory culture for SM between 2008 and 2014. Rate of decline in FEV1 and hospitalization rates prior to and following incident SM infection were analyzed using segmented regression analysis of interrupted time series. ResultsMean (SD) age was 17.4 (9.2) years and the mean (SD) FEV1 % predicted at acquisition was 90.0% (25.2). A total of 44% developed chronic SM infection. In regression analysis adjusted for clinical and demographic factors, there was worsening of the mean annual decline in FEV1 % predicted from -1.79 (95%CI: -2.43, -1.15) pre-acquisition to -2.14 (95%CI: -2.61, -1.67) post-acquisition (P=0.005). A significant change was observed in those with either subsequent intermittent or chronic infection. The mean annual hospitalization rate increased significantly in the subgroup with chronic infection from 0.46 (95%CI: 0.33, 0.60) to 0.88 (95%CI: 0.68, 1.07) (P=0.007). ConclusionsIn this single-center cohort, acquisition of SM in CF was associated with an acceleration in lung function decline. Among those with chronic colonization, acquisition was also associated with increased hospitalization rates.
引用
收藏
页码:1276 / 1282
页数:7
相关论文
共 50 条
  • [1] Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis
    Dalboge, C. S.
    Hansen, C. R.
    Pressler, T.
    Hoiby, N.
    Johansen, H. K.
    JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (05) : 318 - 325
  • [2] Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients
    Waters, Valerie
    Atenafu, Eshetu G.
    Lu, Annie
    Yau, Yvonne
    Tullis, Elizabeth
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (05) : 482 - 486
  • [3] Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients
    Stanojevic, Sanja
    Ratjen, Felix
    Stephens, Derek
    Lu, Annie
    Yau, Yvonne
    Tullis, Elizabeth
    Waters, Valerie
    JOURNAL OF CYSTIC FIBROSIS, 2013, 12 (06) : 575 - 583
  • [4] Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis
    Waters, Valerie
    Atenafu, Eshetu G.
    Salazar, Juliana Giraldo
    Lu, Annie
    Yau, Yvonne
    Matukas, Larissa
    Tullis, Elizabeth
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (01) : 8 - 13
  • [5] The airway microbiome of persons with cystic fibrosis correlates with acquisition and microbiological outcomes of incident Stenotrophomonas maltophilia infection
    Bowron, Lauren
    Acosta, Nicole
    Thornton, Christina
    Carpentero, Jennifer
    Waddell, Barbara-Jean
    Bharadwaj, Lalit
    Ebbert, Kirsten
    Castaneda-Mogollon, Daniel
    Conly, John
    Rabin, Harvey
    Surette, Michael
    Parkins, Michael
    FRONTIERS IN MICROBIOLOGY, 2024, 15
  • [6] Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen
    Hansen, Christine R.
    CURRENT OPINION IN PULMONARY MEDICINE, 2012, 18 (06) : 628 - 631
  • [7] Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis
    Amin, Reshma
    Waters, Valerie
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
  • [8] Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis
    Amin, Reshma
    Waters, Valerie
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04):
  • [9] Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis
    Talmaciu, I
    Varlotta, L
    Mortensen, J
    Schidlow, DV
    PEDIATRIC PULMONOLOGY, 2000, 30 (01) : 10 - 15
  • [10] Stenotrophomonas maltophilia in Cystic Fibrosis Serologic Response and Effect on Lung Diseaseaaa
    Waters, Valerie
    Yau, Yvonne
    Prasad, Sudha
    Lu, Annie
    Atenafu, Eshetu
    Crandall, Ian
    Tom, Stephanie
    Tullis, Elizabeth
    Ratjen, Felix
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (05) : 635 - 640